Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson’s Disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson’s Disease
Authors
Keywords
-
Journal
Parkinsons Disease
Volume 2014, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2014-10-16
DOI
10.1155/2014/903796
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies
- (2014) M.J. Stuart et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment
- (2013) Daniel Lindqvist et al. BRAIN BEHAVIOR AND IMMUNITY
- Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia
- (2013) Elson Asevedo et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Current status of chemokines in the adult CNS
- (2013) Annabelle Réaux-Le Goazigo et al. PROGRESS IN NEUROBIOLOGY
- Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
- (2012) Holly D. Soares ARCHIVES OF NEUROLOGY
- A cytokine study of adult patients with obsessive-compulsive disorder
- (2012) Leonardo F Fontenelle et al. COMPREHENSIVE PSYCHIATRY
- Chemokines in bipolar disorder: Trait or state?
- (2012) Izabela Guimarães Barbosa et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- The Soluble Isoform of CX3CL1 Is Necessary for Neuroprotection in a Mouse Model of Parkinson's Disease
- (2012) J. M. Morganti et al. JOURNAL OF NEUROSCIENCE
- Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
- (2012) Louise M. Collins et al. NEUROPHARMACOLOGY
- Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
- (2012) Daniel Lindqvist et al. PLoS One
- Peripheral chemokine levels in women with recurrent major depression with suicidal ideation
- (2012) Rodrigo Grassi-Oliveira et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Brief Cognitive Assessment in the Early Stages of Parkinson Disease
- (2011) Paulo Bugalho et al. Cognitive and Behavioral Neurology
- Depression in Parkinson disease—epidemiology, mechanisms and management
- (2011) Dag Aarsland et al. Nature Reviews Neurology
- Serum Levels of Chemokines in Parkinson’s Disease
- (2011) Paula Scalzo et al. NEUROIMMUNOMODULATION
- α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells
- (2011) Neda Saffarian Tousi et al. NEUROSCIENCE LETTERS
- Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
- (2010) Alice S. Chen-Plotkin et al. ANNALS OF NEUROLOGY
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
- (2010) Min Shi et al. ANNALS OF NEUROLOGY
- The Genetics of Parkinson Disease
- (2010) Lynn M. Bekris et al. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson's Disease
- (2010) M. Menza et al. PSYCHOSOMATICS
- Neuropsychiatry of Parkinson's disease
- (2009) Arthur Kummer et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release
- (2009) A. Guyon et al. NEUROSCIENCE
- CXCR4 and CXCL12 Expression is Increased in the Nigro-Striatal System of Parkinson’s Disease
- (2009) Mika Shimoji et al. NEUROTOXICITY RESEARCH
- Peripheral cytokines profile in Parkinson’s disease
- (2008) M. Reale et al. BRAIN BEHAVIOR AND IMMUNITY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More